Q2 EPS Estimate for OnKure Therapeutics Increased by Analyst

OnKure Therapeutics (NASDAQ:OKUR) – Research analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of OnKure Therapeutics in a research note issued on Tuesday, May 6th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($1.21) for the quarter, up from their prior estimate of ($1.28). The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.12) EPS, FY2025 earnings at ($4.75) EPS, FY2026 earnings at ($3.91) EPS and FY2027 earnings at ($4.80) EPS.

A number of other brokerages also recently commented on OKUR. HC Wainwright lowered their price objective on OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Oppenheimer lowered their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday, March 11th. Finally, Evercore ISI initiated coverage on shares of OnKure Therapeutics in a research report on Wednesday, April 30th. They issued an “outperform” rating on the stock. Four equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Trading Down 4.5 %

Shares of OnKure Therapeutics stock opened at $1.91 on Friday. The stock has a market capitalization of $25.66 million, a price-to-earnings ratio of -0.16 and a beta of 0.40. OnKure Therapeutics has a twelve month low of $1.83 and a twelve month high of $20.00. The business’s 50 day simple moving average is $3.60 and its 200-day simple moving average is $7.95.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.19) earnings per share for the quarter, topping the consensus estimate of ($1.41) by $0.22.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OKUR. Acorn Capital Advisors LLC bought a new stake in shares of OnKure Therapeutics during the fourth quarter valued at about $12,381,000. Citadel Advisors LLC acquired a new position in OnKure Therapeutics during the 4th quarter valued at about $8,782,000. Samsara BioCapital LLC bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth about $7,088,000. Vestal Point Capital LP acquired a new stake in shares of OnKure Therapeutics in the 4th quarter worth approximately $5,461,000. Finally, Deep Track Capital LP acquired a new stake in shares of OnKure Therapeutics in the 4th quarter worth approximately $4,506,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.